Introduction: In recent years, the repurposing of existing drugs for novel therapeutic purposes has gained significant attention in the field of oncology. Among these, fenbendazole, a broad-spectrum anthelmintic medication primarily used in veterinary medicine to treat parasitic infections in animals, has emerged as a promising candidate for cancer treatment. While initially overlooked in the realm of oncology, mounting preclinical evidence and anecdotal reports have sparked interest in exploring fenbendazole’s anti-cancer properties.

Fenbendazole Mechanism of Action: Fenbendazole exerts its anthelmintic effect by inhibiting microtubule synthesis in parasitic cells, leading to disruption of cellular processes essential for their survival. Interestingly, emerging research suggests that fenbendazole may also possess anti-cancer properties through similar mechanisms. Preclinical studies have demonstrated its ability to inhibit cancer cell proliferation, induce apoptosis, and impede tumor growth in various cancer models. Furthermore, fenbendazole’s potential to target cancer stem cells, a subset of cells implicated in tumor initiation, progression, and therapy resistance, highlights its multifaceted anti-cancer effects.

Clinical Applications and Challenges: Despite promising preclinical data, the translation of fenbendazole from bench to bedside faces several challenges. Limited clinical trials investigating its efficacy and safety in cancer patients pose a significant hurdle in establishing fenbendazole as a standard therapeutic option. Additionally, concerns regarding optimal dosing regimens, potential drug interactions, and adverse effects warrant careful consideration in clinical practice. However, the growing interest in fenbendazole among clinicians and researchers underscores the need for further exploration through well-designed clinical studies to elucidate its therapeutic potential and optimize its use in cancer management.

Conclusion: In conclusion, fenbendazole holds promise as a repurposed drug in cancer treatment, owing to its demonstrated anti-cancer properties and favorable safety profile. While preclinical evidence is encouraging, its clinical utility remains to be fully elucidated. Moving forward, collaborative efforts between clinicians, researchers, and pharmaceutical companies are essential to bridge the gap between preclinical findings and clinical applications, ultimately unlocking the therapeutic potential of fenbendazole in the fight against cancer. fenbendazole for cancer